Literature DB >> 8753775

Relaxed specificity of matrix metalloproteinases (MMPS) and TIMP insensitivity of tumor necrosis factor-alpha (TNF-alpha) production suggest the major TNF-alpha converting enzyme is not an MMP.

R A Black1, F H Durie, C Otten-Evans, R Miller, J L Slack, D H Lynch, B Castner, K M Mohler, M Gerhart, R S Johnson, Y Itoh, Y Okada, H Nagase.   

Abstract

Tumor necrosis factor-alpha is released from cells by a proteolytic cleavage. Previous work suggested that a specific, non-matrix metalloproteinase carries out this cleavage, but matrix metalloproteinases have also been implicated. In this paper, we report that none of the matrix metalloproteinases tested cleaved peptide substrates as specifically as the non-matrix metalloproteinase. A matrix metalloproteinase did process tumor necrosis factor-alpha extracted from COS cells, but neither tissue inhibitor of metalloproteinases-1 nor -2 blocked tumor necrosis factor-alpha processing by human monocytes. Moreover, tissue inhibitor of metalloproteinases-1 had at most a partial effect on the in vivo release of the cytokine in mice. We conclude that a non-matrix metalloproteinase is the major physiological tumor necrosis factor-alpha convertase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8753775     DOI: 10.1006/bbrc.1996.1186

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Anti-TNF antibody treatment of Crohn's disease.

Authors:  S J van Deventer
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Vascular Dysfunction in Brain Hemorrhage: Translational Pathways to Developing New Treatments from Old Targets.

Authors:  Paul A Lapchak; Qiang Wu
Journal:  J Neurol Neurophysiol       Date:  2011

3.  Engineering N-terminal domain of tissue inhibitor of metalloproteinase (TIMP)-3 to be a better inhibitor against tumour necrosis factor-alpha-converting enzyme.

Authors:  Meng-Huee Lee; Vandana Verma; Klaus Maskos; Deepa Nath; Vera Knäuper; Philippa Dodds; Augustin Amour; Gillian Murphy
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

4.  Brain distribution and elimination of recombinant human TIMP-1 after cerebral ischemia and reperfusion in rats.

Authors:  Yalian Sa; Jinsong Hao; Divya Samineni; Joseph Clark; Gail Pyne-Geithman; Joseph Broderick; Aigang Lu
Journal:  Neurol Res       Date:  2011-05       Impact factor: 2.448

5.  Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states.

Authors:  A Pagenstecher; A K Stalder; C L Kincaid; S D Shapiro; I L Campbell
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

Review 6.  Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment.

Authors:  Paul A Lapchak
Journal:  Curr Neurol Neurosci Rep       Date:  2002-01       Impact factor: 5.081

7.  Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme.

Authors:  K Maskos; C Fernandez-Catalan; R Huber; G P Bourenkov; H Bartunik; G A Ellestad; P Reddy; M F Wolfson; C T Rauch; B J Castner; R Davis; H R Clarke; M Petersen; J N Fitzner; D P Cerretti; C J March; R J Paxton; R A Black; W Bode
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

8.  Mechanism of three inhibitors of TACE in blocking the converting of pro-TNF alpha into sTNF alpha.

Authors:  Zhen Wang; Yin Wang; Kongli Zhu; Lianjun Guo; Yuzhen Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2003

9.  PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1).

Authors:  Jyotica Batra; Jessica Robinson; Christine Mehner; Alexandra Hockla; Erin Miller; Derek C Radisky; Evette S Radisky
Journal:  PLoS One       Date:  2012-11-20       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.